Overcoming obstacles to the effective immunotherapy of human cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 35, 2008, Pages 12643-12644

  Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL DESTRUCTION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CD8+ T LYMPHOCYTE; CELL TRANSFER; DOWN REGULATION; EFFECTOR CELL; EX VIVO STUDY; FOOD AND DRUG ADMINISTRATION; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; KIDNEY METASTASIS; LYMPHOCYTE DEPLETION; NONHUMAN; NOTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SKIN METASTASIS; T LYMPHOCYTE ACTIVATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MALE; MICE; NEOPLASMS; RATS;

EID: 51349095229     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0806877105     Document Type: Note

References (20)

1. + T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci USA 105:13003-13008.
2. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:299-308.
3. Rosenberg SA, et al. (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. J Am Med Assoc 271:907-913.
4. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: Moving beyond current vaccines. Nat Med 10:909-915.
5. Dudley ME, et al. (2002) Cancer regression and autoimmunity in patients following clonal repopulation with anti-tumor lymphocytes. Science 298:850-854.
6. Dudley ME, et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346-2357.
7. Overwijk WW, et al. (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198:569-580.
8. Rosenberg SA, et al. (2005) Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 175:6169-6176.
9. O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C (2008) Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 223:114-131.
10. Wrzesinski SH, Wan YY, Flavell RA (2007) Transforming growth factor-beta and the immune response: Implications for anticancer therapy. Clin Cancer Res 13:5262-5270.
11. Kronenberg M, Rudensky A (2005) Regulation of immunity by self-reactive T cells. Nature 435:598-604.
12. Serafini P, Borrello I, Bronte V (2006) Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immunesuppression. Semin Cancer Biol 16:53-65.
13. Barber DL, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687.
14. Korman AJ, Peggs KS, Allison JP (2006) Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297-339.
15. Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP (2006) Adoptive immunotherapy for cancer: Building on success. Nat Rev Immunol 6:383-393.
16. Van Pel A, et al. (1995) Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 145:229-250.
17. Rosenberg SA (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281-287.
18. Morgan RA, et al. (2003) High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 171:3287-3295.
19. + T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 22:117-129.
20. Morgan RA, et al. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129.